Summary
Danaher Corporation's first quarter 2020 results, ending April 3, 2020, demonstrate resilience and strategic expansion amidst the burgeoning COVID-19 pandemic. The company reported a 3.0% increase in overall revenue and a 4.5% increase in core sales, indicating the underlying strength of its diversified businesses prior to the pandemic's full impact late in the quarter. Net earnings from continuing operations significantly rose year-over-year, largely due to a favorable tax provision comparison. A major event during the quarter was the significant acquisition of Cytiva on March 31, 2020, for approximately $20.7 billion, a move expected to bolster the Life Sciences segment. However, the report also highlights the growing uncertainty and potential adverse impacts of COVID-19 on future operations, with a greater negative impact anticipated in the second quarter of 2020.
Financial Highlights
51 data points| Revenue | $4.34B |
| Cost of Revenue | $1.90B |
| Gross Profit | $2.44B |
| R&D Expenses | $287.00M |
| SG&A Expenses | $1.46B |
| Operating Income | $698.00M |
| Interest Expense | $47.00M |
| Net Income | $595.00M |
| EPS (Basic) | $0.83 |
| EPS (Diluted) | $0.81 |
| Shares Outstanding (Basic) | 697.20M |
| Shares Outstanding (Diluted) | 707.90M |
Key Highlights
- 1Total revenue increased by 3.0% to $4.34 billion, with core sales growing by 4.5% year-over-year, demonstrating underlying business strength before the full impact of COVID-19.
- 2Net earnings from continuing operations significantly increased to $595 million from $332 million in the prior year, driven primarily by a favorable tax provision comparison.
- 3Completed the transformative acquisition of Cytiva (formerly GE’s Biopharma business) for approximately $20.7 billion on March 31, 2020, significantly expanding the Life Sciences segment.
- 4Anticipates a greater negative impact from COVID-19 in the second quarter of 2020 compared to the first quarter, given the timing of global spread and shutdown measures.
- 5Life Sciences segment revenue grew 1.5% to $1.65 billion, with core revenue growth of 2.5%, supported by demand in bioprocessing and COVID-19 related testing, though offset by broader market slowdowns.
- 6Diagnostics segment revenue increased by 6.0% to $1.63 billion, with strong core revenue growth of 8.0%, driven by molecular and acute care diagnostics, including demand for COVID-19 testing solutions.
- 7The company strengthened its liquidity position by borrowing an aggregate of $5.0 billion under credit facilities and issuing approximately $2.7 billion in euro-denominated debt in March and April 2020 to manage the impacts of COVID-19 and fund operations.